>> IL-9 is in MEDI's hands. If they drop it, it becomes more important, not less, to have a pulmonary specialist to find a new partner or continue the development internally. <<
My hypothesis is that Holroyd quit on his own volition. The suddenness of the action (evidenced, as you noted, by the need for an “acting” CMO) also points in that direction.
Market Data 
Markets 
AI
